TrialBritish journal of cancer2022

Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.